2025 annual financial data
BioCryst Pharmaceuticals 2025 Operating margin
BioCryst Pharmaceuticals 2025 operating margin with verified reported values.
Direct answer
Operating margin was 38.98%.
Operating income was 340,989,000 USD and net income was 263,861,000 USD.
Operating cash flow was 329,880,000 USD.
Get free BioCryst Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 874,837,000 USD
- Operating income
- 340,989,000 USD
- Net income
- 263,861,000 USD
- Operating cash flow
- 329,880,000 USD